Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia

Clinical Infectious Diseases

Volumn 51, Issue 1, 2010, Pages 15-22

  Johnstone, Jennie ^a   Eurich, Dean T ^b   Minhas, Jasjeet K ^c   Marrie, Thomas J ^d   Majumdar, Sumit R ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b Carolina Global Breastfeeding Institute   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CANADA; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL VACCINES; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 77953756836     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653114     Document Type: Article

References (31)

1. Marrie T, ed. Community acquired pneumonia. New York: Kluwer Academic/Plenum Publishers, 2001.
2. Scott G, ed. Infectious diseases. Canada, Ottawa, Ontario: Centre for Chronic Disease Prevention and Control Health Canada State, 2001.
3. Macfarlane J, Boswell T, Douglas G, et al. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56(Suppl 4):iv1-iv64.
4. Johnstone J, Marrie T, Eurich D, Majumdar S. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007;167:1938-1943. (Pubitemid 47606632)
5. Marrie T, Carriere K, Jin Y, Johnson. D. Mortality during hospitalization for pneumonia in Edmonton, Alberta is associated with physician volume. Eur Respir J 2003;22:148-155.
6. Johnstone J, Eurich D, Majumdar S, Jin Y, Marrie T. Long-term morbidity and mortality after hospitalization with community acquired pneumonia: population based cohort study. Medicine 2008; 87:329334.
7. Mandeli L, Wunderink R, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72. (Pubitemid 46290553)
8. Plotkin S, Orenstein W, eds. Vaccines. 4th ed. Philadelphia: WB Saunders, 2004.
9. Jackson L, Neužil K, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755. (Pubitemid 36514705)
10. Moberley S, Holden J, Tatham D, Andrews R. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008 (1):CD000422.
11. Huss A, Scott P, Stuck A, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180:48-58.
12. Fisman D, Abrutyn E, Spaude K, et al. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community acquired pneumonia. Clin Infect Dis 2006;42:1093-1101.
13. Fedson D. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999;17:S85-S90. (Pubitemid 29366941)
14. Ortqvist A, Hedulnd J, Burman L, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403. (Pubitemid 28064163)
15. Marrie T, Lau C, Wheeler S, et al. A controlled trial of a critical pathway for treatment of community acquired pneumonia. JAMA 2000; 283: 749-755. (Pubitemid 30084614)
16. Feagan BG. A controlled trial of a clinical pathway for treating community-acquired pneumonia. Pharmacotherapy 2001;21:895-945.
17. Fine M, Auble T, Yealy D, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250. (Pubitemid 27044625)
18. Golmohammadi K, Nguyen T, Hanrahan A, et al. Immunization coverage against invasive pneumococcal disease among children in the capital health region of Alberta. Can Commun Dis Rep 2005; 31:65-68.
19. Lynch J, Zhanel G. Streptococcus pneumoniae, epidemiology, risk factors and strategies for prevention. Semin Respir Crit Care Med 2009; 30: 189-209.
20. Laupland K, Gregson D, Flemons W, et al. Burden of community-onset bloodstream infection: a population based assessment. Epidemiol Infect 2007;135:1037-1042. (Pubitemid 47616487)
21. Majumdar S, McAlister F, Eurich D, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999-1001.
22. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
23. Hedlund J, Ortqvist A, Kalin M, et al. Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet 1992; 340:396397.
24. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198: 1019-1027.
25. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Bianco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009; 103:309-316.
26. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8): 1-24.
27. Kellner J, Scheitele D, Vanderkooi O, et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J 2008;27:526-532.
28. Whitney C, Farley M, Haldler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746. (Pubitemid 36514704)
29. Lexau C, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-2050.
30. Poehling K, Talbot T, Griffin M, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668-1674.
31. Tyrrell G, Lovgren M, Chui N, et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 2009;27:3553-3560.